SUMMARY OF KEY OUTCOMES

Warning: The NCBI web site requires JavaScript to function. more...

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

OnabotulinumtoxinA for Injection (Botox): For the Treatment of Overactive Bladder [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Jul.

Cover of OnabotulinumtoxinA for Injection (Botox)

OnabotulinumtoxinA for Injection (Botox): For the Treatment of Overactive Bladder [Internet].

Show details

Contents

< Prev Next >

APPENDIX 2SUMMARY OF KEY OUTCOMES

Table 12When Considering only Costs, Outcomes, and Quality of Life, How Attractive is OnabotulinumtoxinA Relative to Best Supportive Care?

Ona A Versus Best Supportive Care	Attractive	Slightly Attractive	Slightly Unattractive
Costs (total)			X
Drug treatment costs alone			X
Clinical outcomes		X
Quality of life		X
Incremental CE ratio or net benefit calculation	Manufacturer’s base case: $34,029 per QALY gained

: CE = cost-effectiveness; NA = not applicable; QALY = quality-adjusted life-year.

You are permitted to make copies of this document for non-commercial purposes, provided it is not modified when reproduced and appropriate credit is given to CADTH. You may not otherwise copy, modify, translate, post on a website, store electronically, republish, or redistribute any material from this document in any form or by any means without the prior written permission of CADTH.

Please contact CADTH’s Vice-President of Corporate Services at ac.htdac@secivresetaroproc with any inquiries about this notice or other legal matters relating to CADTH’s services.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Bookshelf ID: NBK349311

Contents

< Prev Next >

PubReader
Print View
Cite this Page
OnabotulinumtoxinA for Injection (Botox): For the Treatment of Overactive Bladder [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Jul. APPENDIX 2, SUMMARY OF KEY OUTCOMES.